ALEXION PHARMACEUTICALS, INC.

ALEXION PHARMACEUTICALS, INC. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1992-01-01
Employees
3.8K
Market Cap
-
Website
http://www.alexion.com
Clinical Trials
Related News

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Phase 2
Terminated
Conditions
Dermatomyositis
Interventions
Drug: Ravulizumab
Drug: Placebo
First Posted Date
2021-08-10
Last Posted Date
2024-12-06
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
38
Registration Number
NCT04999020
Locations
🇬🇧

Research Site, Salford, United Kingdom

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Phase 2
Withdrawn
Conditions
Generalized Myasthenia Gravis
Interventions
Drug: ALXN1830
Other: Placebo
First Posted Date
2021-07-29
Last Posted Date
2022-02-11
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Registration Number
NCT04982289
Locations
🇺🇸

Clinical Study Site, Phoenix, Arizona, United States

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

Phase 1
Completed
Conditions
Hypophosphatasia
Interventions
Biological: ALXN1850
First Posted Date
2021-07-28
Last Posted Date
2023-12-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
15
Registration Number
NCT04980248
Locations
🇺🇸

Clinical Trial Site, Nashville, Tennessee, United States

Study in Adult and Pediatric Patients With HSCT-TMA

First Posted Date
2021-07-21
Last Posted Date
2022-05-12
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Registration Number
NCT04970004
Locations
🇺🇸

Clinical Trial Site, Salt Lake City, Utah, United States

Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Acoramidis
First Posted Date
2021-07-12
Last Posted Date
2021-09-24
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
18
Registration Number
NCT04958135
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

First Posted Date
2021-07-09
Last Posted Date
2022-02-11
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Registration Number
NCT04956276
Locations
🇺🇸

Clinical Study Site, Riverside, California, United States

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ALXN2050
Drug: Placebo
First Posted Date
2021-07-07
Last Posted Date
2022-12-09
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
20
Registration Number
NCT04952545
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants

First Posted Date
2021-06-25
Last Posted Date
2021-06-25
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
26
Registration Number
NCT04940559
Locations
🇳🇿

Clinical Trial Site, Auckland, New Zealand

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Phase 1
Completed
Conditions
Healthy
Renal Dysfunction
Interventions
Drug: Danicopan
First Posted Date
2021-06-23
Last Posted Date
2021-06-23
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
16
Registration Number
NCT04935294
Locations
🇺🇸

Clinical Trial Site, Saint Paul, Minnesota, United States

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ALXN2050
Drug: Fluconazole
Drug: Rifampin
First Posted Date
2021-06-22
Last Posted Date
2022-12-08
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
16
Registration Number
NCT04933682
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy